Citi downgrades Steel Dynamics (STLD) but remains positive on long-term outlook
Get Alerts STLD Hot Sheet
Rating Summary:
15 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 6 | New: 31
Join SI Premium – FREE
Citi downgraded Steel Dynamics, Inc. (NASDAQ: STLD) to a Neutral rating (From Buy) and raised the target price on the stock to $130.00 (From $110.00) ahead of the company’s 4Q earnings release.
Citi remains positive on the long-term outlook for Steel Dynamics. However, the stock has significantly outperformed peers, and closed up the historical EV/EBITDA gap with NUE. NUE and STLD are trading at 7-8x normalized EBITDA on Citi’s estimates, in line with historical, suggesting that the market is somewhat aligned with Citi’s view.
In the long-term, Citi believes that this is the “best steel market in a generation.” Analyst, Alexander Hacking wrote in a note, “We see a potential 5–10 year window of super-profits for the US steel sector driven by a combination of supply-side issues (tariffs, consolidation, greater discipline & ESG) and potential demand-side drivers (infrastructure & reshoring). Decarbonization appears an opportunity, more so than a risk, given that the US industry is likely the cleanest in the world (already ~70% EAF).”
In the short term, Citi sees headwinds, as the sheet markets appear inflated by temporary re-stocking demand and prices well above import parity. Hacking continued in the note, saying “We don’t expect an imminent correct with lead-times still expanding but caution is warranted. We acknowledge that we missed the strength of this restock as inventory data showed normal levels & we should have paid more attention to the ~4mt lower shipments to service centers in 2022 vs 2021. Construction steel demand may also face an air-pocket driven by Fed hikes and slowing e-commerce demand.”
Shares of STLD are down 7.68% near mid-day trading on Wednesday.
By Michael Elkins | [email protected]
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Protagonist Therapeutics (PTGX) PT Raised to $170 at H.C. Wainwright
- Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
- UBS Downgrades Shanghai Chicmax Cosmetic (2145:HK) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT Change, Hot ListRelated Entities
Citi, Earnings, Michael ElkinsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share